SUGAI CHEMICAL INDUSTRY CO., LTD.

Business Details

A single-segment company engaged in the manufacture, sale, research, and services of intermediates (for agrochemicals, pharmaceuticals, functional applications, and other uses) and surfactants based on organic chemical synthesis. Domestic sales account for approximately 92% (FY2026 (ending March 2026)), and the company adopts a production method based on order forecasts. Its competitive advantage stems from organic synthesis technology and know-how accumulated over many years, supported by a flexible production-switching system using multi-purpose plants. Factories are located in Wakayama City and Fukui City.

Recent Overview

Although pharmaceutical intermediates saw a significant sales decline, this was offset by growth in agrochemical and functional intermediates; net income increased 27% year-on-year due to recorded extraordinary gains

In FY2026 (ending March 2026), pharmaceutical intermediates saw a significant sales decline of ¥1,258 million (-75.4%) year-on-year, but this was offset by growth in agrochemical intermediates (+¥694 million, +19.2%) and functional intermediates (+¥369 million, +46.2%), resulting in total net sales of ¥6,432 million (-2.9%). Operating income declined to ¥489 million (-9.6%), partly due to increased depreciation expenses. On the other hand, income before income taxes expanded to ¥634 million due to recorded extraordinary gains, including a reversal of provision for loss on litigation of ¥38 million, a reversal of provision for demolition and removal of ¥9 million, and insurance income of ¥30 million, resulting in net income for the period of ¥461 million (+27.0%). Net assets increased to ¥8,365 million (+12.2%) due to a rise in the fair value of investment securities (+¥759 million). For FY2027 (ending March 2027), due to uncertainty surrounding the Middle East situation, the company will disclose its profit forecast at a later date, and has only announced net sales of ¥6,500 million (+1.0%). A change in the representative director and president (Mr. Takashi Taneji is scheduled to assume the position) was also announced.

Key Products

Growth Drivers

• Expanding demand for new functional intermediate products (for photosensitive resins and generative AI-related semiconductors) (+46.2% in FY2026 (ending March 2026))
• Increased sales of agrochemical intermediates driven by growing demand for veterinary drug and acaricide applications, among others (+19.2% in FY2026 (ending March 2026))
• Expected export recovery for pharmaceutical intermediates for European markets as inventory adjustments are completed (forecast export sales of ¥874 million in FY2027 (ending March 2027), +77.6%)
• Continued development of proprietary new functional intermediate products and exploration and launch of next-generation new products
• Diversification of product categories leveraging the flexible production-switching system enabled by multi-purpose plants
• Improved net assets and equity ratio (68.6%) due to rising fair value of investment securities

Risks

• Risk of difficulty in procuring naphtha-derived raw materials and price increases due to escalating tensions in the Middle East (risk of Strait of Hormuz closure)
• Risk of demand fluctuation for pharmaceutical intermediates (a structure dependent on customer inventory adjustments and final product sales conditions)
• Risk of demand fluctuation for agrochemical intermediates due to weather and pest occurrence conditions
• Increased dependence on the domestic revenue base due to a significant decline in the export ratio (14.8% to 7.7%)
• Profit pressure from increased depreciation expenses (from ¥454 million in the prior period to ¥496 million in the current period)
• Impact of foreign exchange rate fluctuations on net sales and purchases (due to foreign currency-denominated transactions)
• Interest rate fluctuation risk (interest-bearing debt balance of ¥1,423 million, addressed through interest rate swap contracts and a ¥20 million commitment line)
• Risk of production stoppage due to factory fires, soil contamination, natural disasters, etc. (at two sites in Wakayama and Fukui)
• Risk of information system failure or information leakage due to cyberattacks or unauthorized access
• Risk of share price fluctuations affecting held securities (investment securities of ¥2,523 million, with unrealized gains of ¥1,429 million)